Profound Medical (PROF) Corporate presentation summary

Strategic focus and product overview

• Emphasis on growing topline with TULSA-PRO for prostate ablation and advancing Sonalleve for gynecological and oncology indications, with FDA approval for osteoid osteoma.

• TULSA-PRO targets both benign and malignant prostate tissue, while Sonalleve is used for adenomyosis, uterine fibroids, and is in trials for other cancers.

Clinical evidence and value proposition

• Over 70 peer-reviewed publications and 200+ conference presentations support TULSA-PRO's efficacy across a range of prostate indications.

• TULSA offers customizable, minimally invasive treatments with reduced side effects, rapid recovery, and no blood loss.

• AI-driven software enhances workflow, precision, and ablation confidence, enabling up to six treatments per day.

Market opportunity and competitive positioning

• U.S. annual addressable market for TULSA-PRO estimated at $1.6B for prostate cancer and $3.2B for BPH/hybrid cases, with an average procedure price of ~$8,000.

• TULSA is compatible with ~5,000 installed MRIs in the U.S., requiring fewer than 200 sites to reach profitability.

• Medicare payment for TULSA is higher than robotic prostatectomy, and hospitals can achieve profitability even with Medicare patients.